Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Microenvironment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Microenvironment. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2022-002599-35 Sponsor Protocol Number: 2022-1-58-002 Start Date*: 2022-10-21
    Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis
    Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.
    Medical condition: glioma (grade OMS II à IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004567-11 Sponsor Protocol Number: 75911 Start Date*: 2020-12-08
    Sponsor Name:Zealand University Hospital
    Full Title: Effect of Low-dose Interferon-alfa2a on peri operative immune suppression
    Medical condition: pMMR Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004130-15 Sponsor Protocol Number: CRC-AGA-M-A-11 Start Date*: 2014-06-03
    Sponsor Name:Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science
    Full Title: Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia
    Medical condition: Androgenetic Alopecia Hamilton-Norwood IIIv-IV male patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004485-21 Sponsor Protocol Number: HE9A/14 Start Date*: 2015-04-03
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
    Medical condition: Castration resistant bone metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001843-37 Sponsor Protocol Number: 52649 Start Date*: 2019-08-06
    Sponsor Name:Radboud University Medical Center
    Full Title: Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging.
    Medical condition: The aim of this study is to assess differences in tumour microenvironment between HPV positive and HPV negative oropharyngeal head and neck squamous cell carcinoma using [68Ga]Ga-RGD2 PET/CT and p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031117 Oropharyngeal squamous cell carcinoma stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031112 Oropharyngeal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031116 Oropharyngeal squamous cell carcinoma stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031115 Oropharyngeal squamous cell carcinoma stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003778-29 Sponsor Protocol Number: CIFRA Start Date*: 2019-03-06
    Sponsor Name:Istituto Nazionale Tumori G. Pascale
    Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V
    Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000177-37 Sponsor Protocol Number: LITE Start Date*: 2017-09-21
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital
    Full Title: Low-dose IL-2 to expand endogenous regulatory T cells and achieve tolerance in liver transplantation
    Medical condition: Discontinuation of immunosuppression in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10024714 Liver transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003556-23 Sponsor Protocol Number: PROMIT Start Date*: 2019-10-15
    Sponsor Name:University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg
    Full Title: A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade Pre...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022844-19 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Dijon
    Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
    Medical condition: Hodgkin Lymphoma not previously treated
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002904-15 Sponsor Protocol Number: B9991011 Start Date*: 2017-05-18
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIEN...
    Medical condition: Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) SE (Completed) CZ (Prematurely Ended) GB (Completed) ES (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001181-38 Sponsor Protocol Number: AuspiCiOus Start Date*: 2021-07-29
    Sponsor Name:Academic Medical Center
    Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study
    Medical condition: Gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004606-60 Sponsor Protocol Number: BP42772 Start Date*: 2021-06-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W...
    Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Ongoing) DK (Ongoing) HU (Ongoing) BE (Ongoing) FR (Ongoing) IT (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000631-23 Sponsor Protocol Number: BP43963 Start Date*: 2022-11-03
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY OF MULTIPLE DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA
    Medical condition: Unresectable or Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004071-34 Sponsor Protocol Number: PRG-Opioid-06-/03 Start Date*: 2009-01-14
    Sponsor Name:Queen Mary, University of London (QMUL)
    Full Title: A single centre, parallel group, pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling.
    Medical condition: This study is not looking at any disease process
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012350-20 Sponsor Protocol Number: MSC-KTx Start Date*: 2008-01-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: MESENCHYMAL STEM CELLS UNDER BASILIXIMAB/ LOW DOSE RATG TO INDUCE RENAL TRANSPLANT TOLERANCE
    Medical condition: Patients will be those receiving a living-related kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003338-29 Sponsor Protocol Number: MK-3475-100 Start Date*: 2016-04-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer
    Medical condition: A:platinum-resistant or partially platinum-sensitive recurrent ovarian cancer (OC) who received 1 but no more than 3 prior lines of anticancer regimens/local standard following primary or interval ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed) LT (Completed) DE (Completed) FI (Completed) NO (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001165-24 Sponsor Protocol Number: UC-0150/1704 Start Date*: 2018-06-12
    Sponsor Name:UNICANCER
    Full Title: A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnos...
    Medical condition: Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and s...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000894-11 Sponsor Protocol Number: IRST153.04 Start Date*: 2016-04-13
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038029 Rectal adenocarcinoma stage IV LLT
    20.0 100000004864 10001172 Adenocarcinoma of colon stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004239-35 Sponsor Protocol Number: 2017/16 Start Date*: 2019-09-26
    Sponsor Name:Centre Antoine Lacassagne
    Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas
    Medical condition: Soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004552-15 Sponsor Protocol Number: NANO-GBM Start Date*: 2021-03-18
    Sponsor Name:Centre Jean Perrin
    Full Title: Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA